Psoriatic Arthritis

More Than Meets the Eye

Jason Liebowitz, MD, FACR | November 21, 2023

SAN DIEGO—In recent years, the recognition of nr-axSpa has helped identify the cause of back pain in many patients previously without a diagnosis. However, questions remain about how to avoid under- or over-diagnosing the condition. In the session titled, Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis, several speakers provided high-yield insights on this topic. Diagnostic challenges, imaging options and mimics to watch for were among the specific points of discussion.

From Basic Science to Clinical Treatments: An Update on PsA

Jason Liebowitz, MD, FACR | November 16, 2023

Dr. Christopher Ritchlin provided insights into the underlying mechanisms of the immune system that promote disease activity in patients with psoriatic arthritis (PsA), the latest research on how to optimize therapy for PsA and more.

Why Mental Health Screening Is Essential for Patients with Psoriatic Disease

Catherine Kolonko | October 12, 2023

Research suggests that patients with psoriasis and psoriatic arthritis (PsA) have a greater risk of depression, anxiety and, in some cases, substance abuse and dependence than the general population, yet symptoms often go unrecognized and untreated by medical professionals. Both psoriasis and PsA are associated with depression, with up to 30% of patients in either…

FDA Grants Interchangeable Designation to Pfizer’s Abrilada, Biosimilar to AbbVie’s Humira

Keri Losavio | October 5, 2023

On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).

Psoriatic Arthritis Drugs at a Glance, 2023

Mary Choy, PharmD, BCGP, FASHP | April 21, 2023

Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

First Biosimilar to Adalimumab (Humira) Enters the U.S. Market After Years of Legal Battles

Michele B. Kaufman, PharmD, BCGP | January 31, 2023

After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Walter P. Maksymowych, MB ChB, FACP, FRCP(C) | December 1, 2022

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

Challenges in Psoriatic Arthritis

Samantha C. Shapiro, MD | November 29, 2022

PHILADELPHIA—Despite a large and ever-growing number of therapeutic options for our patients with psoriatic disease, it is not uncommon for us come across scenarios in which a patient’s response to therapy does not match our expectations and our shared goals for treatment. We all have those patients—the ones whose joints improve with one drug, but…

Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis

Ashley Krivohlavek | November 29, 2022

PHILADELPHIA—“At age 12, I was diagnosed with psoriasis (PsO), followed by a diagnosis of psoriatic arthritis (PsA) at age 30,” said Ashley Krivohlavek of Oklahoma City in a poster presentation at ACR Convergence 2022. “I’m now 38.” Ms. Krivohlavek’s Story In 2020, I had been on an infused biologic for 18 months, but my…

FDA Approves Ustekinumab for Children with PsA

Michele B. Kaufman, PharmD, BCGP | November 7, 2022

After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.